Linda Coate

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

Rafael Rosell, Urania Dafni, Enriqueta Felip et al. · The Lancet Respiratory Medicine · 2017 · 183 citations

Medicine, Oncology, Pharmacology +12

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson et al. · The Lancet Oncology · 2017 · 122 citations

Medicine, Gynecology, Oncology +13

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Ross A. Soo, Ji‐Youn Han, Urania Dafni et al. · Annals of Oncology · 2021 · 116 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?

Adrian G. Sacher, Lisa W. Le, Natasha B. Leighl et al. · Journal of Thoracic Oncology · 2013 · 108 citations · Full text

Medicine, Geriatric Medicine, Geriatric Assessment +5

A Comparison of Whole-Body MRI and CT for the Staging of Lymphoma

Darren D. Brennan, Tadhg G. Gleeson, Linda Coate et al. · American Journal of Roentgenology · 2005 · 98 citations

Medicine, Oncology, Radiology +13